Syntax Bio is a synthetic biology company programming the next generation of cell therapies. Its proprietary Cellgorithmâ„¢ platform uses a CRISPR-based system to program and accelerate stem cell differentiation, transforming how regenerative medicines are discovered, developed, and manufactured. By replacing slow, labor-intensive differentiation processes with a rapid, programmable approach that mimics human development, Syntax Bio makes cellular generation more reliable and scalable at unprecedented speed, unlocking new possibilities across the biotechnology industry.
| Website | https://www.syntax-bio.com/ |
| Employees | 17 (10 on RocketReach) |
| Founded | 2021 |
| Industry | Biotechnology Research |
| Keywords | Stem Cells, Stem Cell Therapy, Cell Differentiation, Advanced Therapy Medicinal Products, Regenerative Medicine, Cell Therapies, Biotechnology, Pharmaceutical Research, Drug Development, Biopharmaceutical, Life Sciences, Therapeutic Innovation, Clinical Development, Biomedical Research, Translational Research, Cell Engineering, Molecular Biology, Cellular Reprogramming, Gene Therapy |
| Competitors | Moderna Therapeutics, CRISPR Therapeutics, Vertex Pharmaceuticals, Sangamo Therapeutics, Inc., Editas Medicine, bluebird bio, Alnylam Pharmaceuticals, Intellia Therapeutics, Inc., Aduro Biotech is now Chinook Therapeutics, Amgen +37 more (view full list) |
Looking for a particular Syntax Bio employee's phone or email?
John Craighead is the CEO of Syntax Bio.
10 people are employed at Syntax Bio.
Syntax Bio is based in Chicago, Illinois.